% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

  • normanisela normanisela Dec 31, 2013 9:35 PM Flag

    CEO Linda Powers reported / Oppenheimer Healthcare Conference currently in Several Negotiations/Partnering DCVax

    Being that Northwest Biotherapeutics recently engaged in a secondary offering and raised over $50M over the course of this year, the company's financial position is stronger than it has ever been in the past. The current cash position will be more than sufficient enough for the company to pass numerous key upcoming milestones which could have a significant effect on the company's share price. Likewise, the company's CEO Linda Powers reported at the Oppenheimer Healthcare Conference this past week that the company is currently in several negotiations regarding partnering its DCVax Phase III Prostate Cancer clinical trial. If the company is successful at partnering this trial then shareholders could potentially never be at risk of a dilution ever again. However in turn, if upcoming near-term milestones within the next two months are positive, any potential further dilution would likely be minimal due to share price appreciation. Ms. Powers has stated publicly that the company is completely in line with shareholders in terms of wanting to avoid dilution, as most of the company's management have significant investments in company stock

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.774-0.025(-3.19%)May 23 4:00 PMEDT